Abstract
Purpose: Trastuzumab emtansine is routinely offered to patients in the second-line setting for advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancers. There is a paucity of UK real-world data on the progression-free survival (PFS) with trastuzumab emtansine therapy after prior pertuzumab and the risk of cardiotoxicity. Trastuzumab deruxtecan is currently approved for use after 2 or more anti-HER2 therapies based on DESTINY-Breast01 single-arm trial showing an overall response rate of 60.9% and median PFS of 16.4 [1].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
